A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether imlifidase in combination with bortezomib,
belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the
occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic
kidney disease with a positive crossmatch towards their living donor during a period of 3
months from transplantation.